Search results for "antiprotozoal agents"

showing 10 items of 57 documents

Direct synthesis of C3-mono-functionalized oxindoles from N-unprotected 2-oxindole and their antileishmanial activity.

2014

A novel approach for the synthesis of unprecedented C3-mono-functionalized indolin-2-ones is reported, starting from 2-oxindole and chalcones. The reactions proceed regioselectively under mild conditions, without di- and tri-alkylated side products. The new compounds have been evaluated in vitro for their antiproliferative effects against the protozoan Leishmania infantum. Interestingly, they appear able to kill L. infantum promastigotes and amastigotes, without significant cytotoxic effects.

DiastereoselectivityLeishmanicidal activityIndolesStereochemistryClinical BiochemistryAntiprotozoal AgentsDrug Evaluation PreclinicalPharmaceutical Science2-oxindoleChemistry Techniques SyntheticBiochemistryCell LineMiceStructure-Activity RelationshipChalconeMichael additionparasitic diseasesDrug DiscoveryToxicity TestsAnimalsLeishmania infantumAmastigoteMolecular BiologyLeishmaniaOxindoles; Michael addition; Leishmania; Leishmanicidal activity; Diastereoselectivity; CyclizationbiologyDose-Response Relationship DrugChemistryOrganic Chemistrybiology.organism_classificationLeishmaniaCombinatorial chemistryIn vitroOxindolesCyclizationMichael reactionMolecular MedicineOxindoleLeishmania infantumBioorganicmedicinal chemistry
researchProduct

TTAS a New Stilbene Derivative that Induces Apoptosis in Leishmania Infantum

2012

Leishmania parasites are able to undergo apoptosis (programmed cell death), similarly to mammalian cells. Recently it was demonstrated in vitro the anti-leishmanial effect of some natural and synthetic stilbenoids including resveratrol and piceatannol. In this study we evaluated the Leishmanicidal activity of a pool of stilbene derivatives which had previously shown high apoptotic efficacy against neoplastic cells. All the compounds tested were capable to decrease the parasite viability in a dose-dependent manner. Trans-stilbenes proved to be markedly more effective than cis-isomers. This was different from that observed in tumor cells in which cis-stilbenes were more potent cytotoxic agent…

G2 PhaseProgrammed cell deathLeishmaniasiSettore MED/17 - Malattie InfettiveImmunologyAntiprotozoal AgentsTUBULINApoptosisResveratrolChromatography AffinityLethal Dose 50chemistry.chemical_compoundGranulocyte-Macrophage Progenitor CellsAnnexin A5Leishmania infantumCytotoxicityCells CulturedMembrane Potential MitochondrialPiceatannolDose-Response Relationship DrugbiologyGeneral MedicineFlow CytometryHematopoietic Stem Cellsbiology.organism_classificationLeishmaniaPROGRAMMED CELL DEATHIn vitroInfectious DiseaseschemistryBiochemistrySTILBENESAntimony Sodium GluconateApoptosisStilbeneElectrophoresis Polyacrylamide GelParasitologyLeishmania infantumCell DivisionLEISHMANIASIS
researchProduct

Treatment of giardiasis reverses "active" coeliac disease to "latent" coeliac disease.

2001

In patients with coeliac disease, a regression of intestinal damage without a gluten-free diet is a very rare event. We describe a young child with diarrhoea, intestinal mucosa atrophy and positive serum anti-endomysial and anti-tissue transglutaminase (anti-tTG) antibodies during intestinal giardiasis infection. He showed normal intestinal mucosa architecture and negative anti-endomysial and anti-tTG antibodies after his giardiasis was cured, although he continued to assume a normal diet. Re-evaluations on a 6-monthly basis showed that he was symptom free, and all haemato-chemical parameters were within normal limits. Three years after the initial diagnosis, a third intestinal biopsy showe…

GiardiasisMalemedicine.medical_specialtyNormal dietTissue transglutaminaseAntiprotozoal AgentsEnzyme-Linked Immunosorbent AssaySensitivity and SpecificityCoeliac diseaseAtrophyIntestinal mucosaImmunopathologyBiopsyMedicineHumansIntestinal MucosaAutoantibodiesTransglutaminasesHepatologybiologymedicine.diagnostic_testbusiness.industryBiopsy NeedleGastroenterologyInfantmedicine.diseaseImmunohistochemistryImmunoglobulin ACeliac DiseaseImmunologybiology.proteinHistopathologybusinessFollow-Up StudiesEuropean journal of gastroenterologyhepatology
researchProduct

Secondary impairment of pancreatic function as a cause of severe malabsorption in intestinal giardiasis: A case report

1997

We report the case of a 54-year-old male patient hospitalized for diarrhea and weight loss (8 kg over the previous three months). At admission, we observed pale oral and conjunctival mucosa and peripheral edema of the lower limbs. Stool frequency was 8-10 per day. Laboratory data were as follows: hemoglobin, 11 g/dL; total proteins, 4.3 g/dL; albumin, 2 g/dL; pseudocholinesterase, 1248 U/L; triglycerides, 54 mg/dL; serum cholesterol, 102 mg/dL; calcium, 7.9 mg/dL. Fecal fat was 8.2 g/24 hr. Fecal chymotrypsin (FCT) was 2.3 U/g. A duodenal probe was performed after administration of intravenous secretin and cerulein stimulation, and a contemporaneous mucosal biopsy was taken at the ligament …

GiardiasisMalemedicine.medical_specialtyPancreatic diseaseMalabsorptionPeripheral edemaAntiprotozoal AgentsAntitrichomonal AgentsGastroenterologyAsymptomaticMalabsorption SyndromesVirologyInternal medicineMetronidazolemedicineAnimalsHumansbusiness.industryAlbuminMiddle Agedmedicine.diseaseSteatorrheaDiarrheaMetronidazoleInfectious DiseasesEndocrinologyParasitologyExocrine Pancreatic Insufficiencymedicine.symptomGiardia lambliabusinessmedicine.drug
researchProduct

High-throughput screening with the Eimeria tenella CDC2-related kinase2/cyclin complex EtCRK2/EtCYC3a

2012

The poultry disease coccidiosis, caused by infection with Eimeria spp. apicomplexan parasites, is responsible for enormous economic losses to the global poultry industry. The rapid increase of resistance to therapeutic agents, as well as the expense of vaccination with live attenuated vaccines, requires the development of new effective treatments for coccidiosis. Because of their key regulatory function in the eukaryotic cell cycle, cyclin-dependent kinases (CDKs) are prominent drug targets. The Eimeria tenella CDC2-related kinase 2 (EtCRK2) is a validated drug target that can be activated in vitro by the CDK activator XlRINGO (Xenopus laevis rapid inducer of G2/M progression in oocytes). B…

In silicoPlasmodium falciparumAntiprotozoal AgentsDrug Evaluation PreclinicalProtozoan ProteinsMicrobiologyEimeriaMicrobiology03 medical and health sciences0302 clinical medicineCyclin-dependent kinaseCyclinsparasitic diseasesCDC2 Protein KinaseAnimalsEnzyme Inhibitors030304 developmental biologyCyclin0303 health sciencesCyclin-dependent kinase 1biologyKinaseComputational BiologyPlasmodium falciparumCell cyclebiology.organism_classificationVirologyStandard3. Good healthHigh-Throughput Screening Assays030220 oncology & carcinogenesisCell and Molecular Biology of Microbesbiology.proteinEimeria tenellaMicrobiology
researchProduct

Heterocyclic Diamines with Leishmanicidal Activity.

2021

Leishmaniasis is one of the world's most neglected diseases with a worldwide prevalence of 12 million people. There are no effective human vaccines for its prevention, and outdated drugs hamper treatment. Therefore, research aimed at developing new therapeutic tools to fight leishmaniasis remains a crucial goal today. With this purpose in mind, here, we present 10 new compounds made up by linking alkylated ethylenediamine units to pyridine or quinoline heterocycles with promising in vitro and in vivo efficacy against promastigote and amastigote forms of Leishmania infantum, Leishmania donovani, and Leishmania braziliensis species. Three compounds (2, 4, and 5) showed a selectivity index muc…

InfectivitybiologyChemistryLeishmania donovaniAntiprotozoal AgentsLeishmaniasisPharmacologyDiaminesmedicine.diseasebiology.organism_classificationLeishmaniaLeishmania braziliensisLeishmania braziliensisInfectious DiseasesIn vivoparasitic diseasesmedicineHumansLeishmania infantumLeishmania infantumAmastigoteLeishmaniasisACS infectious diseases
researchProduct

Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation.

2015

Novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation were developed; some of them possess K(i) values in the micromolar range. We studied the structure-activity relationship of these derivatives and we performed docking studies, which allowed us to find out the key interactions established by the inhibitors with the target enzyme. Biological results indicate that the nature of the P2 and P3 substituents and their binding to the S2/S3 pockets is strictly interdependent.

InhibitorMolecular modelCell SurvivalClinical BiochemistryTrypanosoma brucei bruceiAntiprotozoal AgentsPharmaceutical ScienceMolecular modelingCysteine Proteinase InhibitorsBiochemistryCell Linechemistry.chemical_compoundMiceStructure-Activity RelationshipCysteine ProteasesDrug DiscoveryAnimalsMolecular Biology3-Bromo isoxazolinechemistry.chemical_classificationDipeptide-likeDipeptideBinding SitesOrganic ChemistryDipeptidesIsoxazolesCombinatorial chemistryProtein Structure TertiaryMolecular Docking SimulationCysteine EndopeptidasesEnzymeRhodesainchemistryWarheadDocking (molecular)Drug DesignMolecular MedicineRhodesain Dipeptide-like 3-Bromo isoxazoline Inhibitor Molecular modelingBioorganicmedicinal chemistry
researchProduct

Triazolopyridopyrimidines: an emerging family of effective DNA photocleavers. DNA binding. Antileishmanial activity.

2015

Triazolopyridopyrimidines 3-phenyl-6,8-di(2-pyridyl)-[1,2,3]triazolo[5',1':6,1]pyrido[2,3-d]pyrimidine (1a), 6,8-di(pyridin-2-yl)-[1,2,3]triazolo[1',5':1,6]pyrido[2,3-d]pyrimidine (1b) and 3-methyl-6,8-di(2-pyridyl)-[1,2,3]triazolo[5',1':6,1]pyrido[2,3-d]pyrimidine (1c) were prepared and their electrochemical and luminescence properties were studied in depth. The DNA binding ability of this series of compounds has been investigated by means of UV-vis absorption and fluorescence titrations, steady-state emission quenching with ferrocyanide as well as viscosity measurements. Results have shown that triazolopyridopyrimidine 1a interacts strongly at DNA grooves. This compound also displays pref…

LuminescencePyrimidineStereochemistryGuaninePyridinesUltraviolet RaysRadicalTriazoleSubstituentAntiprotozoal AgentsBiochemistrychemistry.chemical_compoundStructure-Activity RelationshipParasitic Sensitivity TestsStructure–activity relationshipPhysical and Theoretical ChemistryBinding siteDNA CleavageLeishmaniaBinding SitesDose-Response Relationship DrugMolecular StructureOrganic ChemistryDNAPhotochemical ProcesseschemistryHeterocyclic Compounds 3-RingDNAOrganicbiomolecular chemistry
researchProduct

In vitro activity of scorpiand-like azamacrocycle derivatives in promastigotes and intracellular amastigotes of Leishmania infantum and Leishmania br…

2012

The activity of a family scorpiand-like azamacrocycles against Leishmania infantum and Leishmania braziliensis was studied using promastigotes, axenic and intracellular amastigotes forms. All the compounds are more active and less toxic than meglumine antimoniate (Glucantime). Moreover, the data on infection rates and amastigotes showed that compounds P2Py, PN and P3Py are the most active against both species of Leishmania. On the other hand, studies on the inhibitory effect of these compounds on SOD enzymes showed that while the inhibition of the Fe-SOD enzyme of the promastigote forms of the parasites is remarkable, the inhibition of human CuZn-SOD and Mn-SOD from Escherichia coli is negl…

Macrocyclic CompoundsMeglumine antimoniateAntiprotozoal AgentsLeishmania braziliensisMicrobiologyStructure-Activity RelationshipParasitic Sensitivity TestsDrug DiscoverymedicineLeishmania infantumAmastigoteAxenicPharmacologychemistry.chemical_classificationAza CompoundsbiologyDose-Response Relationship DrugMolecular StructureOrganic ChemistryGeneral MedicineLeishmaniabiology.organism_classificationLeishmania braziliensisEnzymechemistryLeishmania infantumIntracellularmedicine.drugEuropean journal of medicinal chemistry
researchProduct

New Tetromycin Derivatives with Anti-Trypanosomal and Protease Inhibitory Activities

2011

Four new tetromycin derivatives, tetromycins 1-4 and a previously known one, tetromycin B (5) were isolated from Streptomyces axinellae Pol001(T) cultivated from the Mediterranean sponge Axinella polypoides. Structures were assigned using extensive 1D and 2D NMR spectroscopy as well as HRESIMS analysis. The compounds were tested for antiparasitic activities against Leishmania major and Trypanosoma brucei, and for protease inhibition against several cysteine proteases such as falcipain, rhodesain, cathepsin L, cathepsin B, and viral proteases SARS-CoV M(pro), and PL(pro). The compounds showed antiparasitic activities against T. brucei and time-dependent inhibition of cathepsin L-like proteas…

Magnetic Resonance Spectroscopyanti-trypanosomalmedicine.medical_treatmentCathepsin LStreptomyces axinellaePharmaceutical ScienceCathepsin BCathepsin BCathepsin LCathepsin ODrug DiscoveryPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5Coronavirus 3C ProteasesLeishmania major0303 health sciencesbiology030302 biochemistry & molecular biologytetromycin; anti-trypanosomal; protease inhibition; <em>Streptomyces axinellae</em>; marine spongeTrypanocidal AgentsStreptomycesCysteine EndopeptidasesBiochemistrySevere acute respiratory syndrome-related coronavirusStreptomyces axinellaetetromycinBiologiemarine spongeddc:547ProteasesTrypanosoma brucei bruceiAntiprotozoal AgentsTrypanosoma bruceiHeterocyclic Compounds 4 or More RingsArticle03 medical and health sciencesViral ProteinsAxinellaparasitic diseasesmedicineAnimalsProtease Inhibitorsddc:610protease inhibition ; anti-trypanosomal ; Streptomyces axinellae ; tetromycin ; marine sponge030304 developmental biologyCathepsinProteasebiology.organism_classificationprotease inhibitionlcsh:Biology (General)biology.protein
researchProduct